Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etilevodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.64 |
| ▸ | RECQL | P46063 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etilevodopa SCHEMBL584493 | 1.00 | ALOX15 (0.64) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL1069939 | 1.00 | ALOX15 (0.64) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL7291700 | 0.98 | ALOX15 (0.62) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL28278862 | 0.98 | ALOX15 (0.62) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL7063390 | 0.98 | ALOX15 (0.62) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL28209537 | 0.96 | ALOX15 (0.59) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL28067523 | 0.94 | ALOX15 (0.57) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL6140024 | 0.88 | ALOX15 (0.60) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL15679070 | 0.88 | ALOX15 (0.60) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL11402716 | 0.87 | SLC7A5 (0.48) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533417-B2 | L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2026-01-27 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| EP-4595956-A1 | LEVODOPA FATTY ACID DERIVATIVES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE | Dynamic Biologics Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-111801650-B | Electronic device and method for controlling external electronic device based on usage pattern information corresponding to user | 三星电子株式会社 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025075499-A1 | REDUCING DOPAMINE FEED-BACK INHIBITION IN DOPAMINERGIC CELLS BY TADALAFIL. | UNIVERSITEIT VAN AMSTERDAM (NL) | 2025-04-10 | — | — | WO | disclosed |
| US-20250114319-A1 | Levodopa Fatty Acid Derivatives, Formulations Thereof, and Their Uses for the Treatment of Parkinson's Disease | DYNAMIC BIOLOGICS INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250041257-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | INTRANCE MEDICAL SYSTEMS INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025010073-A1 | LEVODOPA FATTY ACID DERIVATIVES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE | DYNAMIC BIOLOGICS INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| CN-119264002-A | Levodopa fatty acid derivative, preparation thereof and application thereof in treatment of parkinsonism | 动态生物公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12036199-B1 | Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of Parkinson's disease | DYNAMIC BIOLOGICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220251295-A1 | LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE | DYNAMIC BIOLOGICS INC (US) | 2022-08-11 | — | — | US | disclosed |
| WO-2022099195-A1 | OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114319-A1 | Levodopa Fatty Acid Derivatives, Formulations Thereof, and Their Uses for the Treatment of Parkinson's Disease | SNCA, PARK7, LRRK2 | DRD3 123/4885ALOX15 140/4885KDM4E 3052/4885 |
| US-20220251295-A1 | LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE | PARK7, ADCY3, PRLHR | DRD3 64/4885ALOX15 695/4885KDM4E 2484/4885 |
| US-12036199-B1 | Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of Parkinson's disease | SNCA, PARK7, LRRK2 | DRD3 123/4885ALOX15 140/4885KDM4E 3052/4885 |
| US-12533417-B2 | L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders | COMT, SLC6A3, DDT | DRD3 452/4885ALOX15 2279/4885KDM4E 2647/4885 |
| US-20250041257-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | COMT, DDT, DDC | DRD3 52/4885ALOX15 1795/4885KDM4E 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.